Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ABVX.NASDAQ

Abivax SA American Depositary Shares (ABVX NASDAQ) stock market data APIs

$12.01 0.15(1.3%) as of July 26, 2024
Price chart is built with Anychart

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Abivax SA American Depositary Shares Financial Data Overview

11.86
12.01
-
12.3
11.62
7.995-17.02
705 M
62 918 K
20 000
0
1.369
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ABVX',
Type: 'Common Stock',
Name: 'Abivax SA American Depositary Shares',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01JLQNZ03',
ISIN: NULL,
CUSIP: NULL,
CIK: '1956827',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2023-10-20',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Abivax SA American Depositary Shares Fundamental Data is available in our Financial Data APIs

  • Net Revenue 20 000
  • EBITDA -73 350 000
  • Earnings Per Share -2.66
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Abivax SA American Depositary Shares Earnings via APIs

  • Latest Release 2024-04-02
  • EPS/Forecast -0.6

Get Abivax SA American Depositary Shares End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Abivax SA American Depositary Shares latest news via APIs

Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis

Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464 Moreover, in the subgr...
  • ABX464 PHASE 2B
  • EURONEXT PARIS
  • MAINTENANCE
  • MAINTENANCE STUDY
  • MAYO SCORE
  • PHASE 2B
  • REMISSION
  • UC
  • ULCERATIVE COLITIS

Abivax Reports 2021 Financial Results and Operations Update

Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of ...
  • ABIVAX SA
  • CHRONIC INFLAMMATORY DISEASES
  • CLINICAL DEVELOPMENT
  • EURONEXT PARIS
  • INFLAMMATORY DISEASE
  • INFLAMMATORY DISEASES
  • UC
  • ULCERATIVE COLITIS
Do you have any questions?
support@eodhistoricaldata.com